Form 4: Humacyte Director Brady W. Dougan Reports Transaction

Director Brady W. Dougan reports a transaction involving Humacyte, Inc. common stock.

Summary

• On August 29, 2024, Brady W. Dougan's spouse purchased 1,222 shares of Humacyte, Inc. common stock at a price of $6.545 per share.
• Following the transaction, Mr. Dougan beneficially owns 510,161 shares directly, 242,054 shares indirectly through his spouse, 1,148,240 shares indirectly through The Niklason Living Trust, and 3,677,262 shares indirectly through Ayabudge LLC.
• The purchase by Mr. Dougan's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934 against a portion of the sale by Ayabudge LLC of 809,786 shares on May 31, 2024.
• Mr. Dougan's spouse has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard reporting of a transaction. The purchase could be seen as slightly positive, but it's a small amount relative to the total shares outstanding.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect broader industry trends but offers insight into the actions of a key individual at Humacyte.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders.

Key Dates